High-Efficacy 5-HT1A Agonists for CNS Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current 5-HT 1A receptor agonists have limited therapeutic efficacy due to their partial agonist properties, which is insufficient for treating central nervous system disorders such as depression and movement disorders, and there is a need for compounds with higher agonist activity and selectivity.
Innovation Solution
Development of novel compounds with the formula (I) that exhibit high affinity and selectivity as high-efficacy agonists for the 5-HT 1A receptor, surpassing the efficacy of existing compounds like befiradol and minimizing activation of dopamine D2 and adrenergic receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If partial agonist compounds like buspirone and tandospirone are used, then they show some therapeutic activity, but their efficacy is limited due to incomplete receptor activation
Solution Approach 1:
The patent modifies molecular parameters of the agonist compounds to achieve full receptor activation. The compounds of formula (I) are designed with specific structural features (aromatic ring systems, basic nitrogen atoms, hydroxyl groups) that enable complete activation of 5-HT1A receptors, transforming the partial agonist limitation into full agonist efficacy while maintaining therapeutic selectivity
2Quantity of substance
If high doses of partial agonists are administered, then receptor occupancy increases, but full activation is still not achieved
Solution Approach 1:
The patent creates novel compound structures that copy and optimize the essential features of serotonin while achieving superior agonist properties. The compounds of formula (I) replicate the pharmacophore elements needed for 5-HT1A receptor activation but with enhanced efficacy, allowing full therapeutic response at lower doses compared to partial agonists
3Reliability
If compounds with high agonist activity are developed, then therapeutic potential increases, but selectivity against other receptors may decrease causing side effects
Solution Approach 1:
The patent applies local quality by designing compounds with specific functional groups positioned to interact selectively with 5-HT1A receptor binding sites. The aromatic rings, basic nitrogen atoms, and hydroxyl groups in formula (I) are arranged to create localized interactions that enhance 5-HT1A affinity and efficacy while minimizing cross-reactivity with dopamine D2 and adrenergic receptors
Data Source
Figure 1
Figure 2A
Figure 2B~2C
AI summary
The invention concerns compounds that possess a high affinity at 5-HT 1A receptors and an agonist efficacy, as measured by Emax values from a cellular activation assay, that is higher than that of the compounds described in prior art. The capacity of the compounds of the invention to activate an effector protein complex is higher than that the most efficacious agonist described in prior art. Compounds of the invention also exhibit an exceptionally high selectivity (Ki ratio greater than 1000-fold) with respect, in particular, to dopamine D2 receptors and adrenergic receptors of the alpha1 subtype. This selectivity which constitutes a great advantage since it means that the compounds will avoid inducing (central and peripheral) effects associated with activating or inhibiting such receptors.